{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T23:23:34Z","timestamp":1791156214940,"version":"4.1.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1016\/j.ijrobp.2013.06.2043","type":"journal-article","created":{"date-parts":[[2013,9,26]],"date-time":"2013-09-26T02:03:54Z","timestamp":1380161034000},"page":"479-486","source":"Crossref","is-referenced-by-count":54,"title":["A Phase 1 Study of Everolimus + Weekly Cisplatin + Intensity Modulated Radiation Therapy in Head-and-Neck Cancer"],"prefix":"10.1016","volume":"87","author":[{"given":"Matthew G.","family":"Fury","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy Y.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Sherman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan L.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shyam","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Heguy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronglai","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Korte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Lisa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Ganly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Snehal","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashok","family":"Shaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jatin","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Haque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Katabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Pfister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2013.06.2043_bib1","doi-asserted-by":"crossref","first-page":"596","DOI":"10.6004\/jnccn.2011.0053","article-title":"National comprehensive cancer network clinical practice guidelines in oncology. Head and neck cancers","author":"Pfister","year":"2011","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ijrobp.2013.06.2043_bib2","doi-asserted-by":"crossref","first-page":"4964","DOI":"10.1158\/1078-0432.CCR-07-1041","article-title":"Dissecting the Akt\/mammalian target of rapamycin signaling network: Emerging results from the head and neck cancer tissue array initiative","volume":"13","author":"Molinolo","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2013.06.2043_bib3","doi-asserted-by":"crossref","first-page":"19024","DOI":"10.1073\/pnas.1111963108","article-title":"Genomic dissection of the epidermal growth factor receptor (EGFR)\/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers","volume":"108","author":"Morris","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ijrobp.2013.06.2043_bib4","doi-asserted-by":"crossref","first-page":"5820","DOI":"10.1158\/1078-0432.CCR-03-0483","article-title":"Overexpressed eIF4E is functionally active in surgical margins of head and neck cancer patients via activation of the Akt\/mammalian target of rapamycin pathway","volume":"10","author":"Nathan","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2013.06.2043_bib5","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1002\/hed.21621","article-title":"Tissue microarray analysis demonstrates association between p16 and phosphorylated eIF4E in tonsillar squamous cell carcinoma","volume":"22","author":"Fury","year":"2011","journal-title":"Head Neck"},{"key":"10.1016\/j.ijrobp.2013.06.2043_bib6","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1158\/1078-0432.CCR-11-2824","article-title":"mTOR as a molecular target of HPV-associated oral and cervical squamous carcinomas","volume":"18","author":"Molinolo","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2013.06.2043_bib7","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1200\/JCO.1999.17.9.2909","article-title":"Analysis of surgical margins with the molecular marker eIF4E: A prognostic factor in patients with head and neck cancer","volume":"17","author":"Nathan","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2013.06.2043_bib8","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1158\/0008-5472.CAN-06-2449","article-title":"Mammalian target of rapamycin inhibitors as possible adjuvant therapy for microscopic residual disease in head and neck squamous cell cancer","volume":"67","author":"Nathan","year":"2007","journal-title":"Cancer Res"},{"issue":"Suppl. 5","key":"10.1016\/j.ijrobp.2013.06.2043_bib9","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.6004\/jnccn.2008.2005","article-title":"NCCN task force report: mTOR inhibition in solid tumors","volume":"6","author":"Figlin","year":"2008","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ijrobp.2013.06.2043_bib10","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.molcel.2006.03.029","article-title":"Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt\/PKB","volume":"22","author":"Sarbassov","year":"2006","journal-title":"Mol Cell"},{"key":"10.1016\/j.ijrobp.2013.06.2043_bib11","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1182\/blood-2006-06-030833","article-title":"Rapamycin derivatives reduce mTORC2 signaling and inhibit Akt activation in AML","volume":"109","author":"Zeng","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2013.06.2043_bib12","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1158\/1535-7163.MCT-08-1184","article-title":"Comparison of radiosensitizing effects of the mammalian target of rapamycin inhibitor CCI-779 to cisplatin in experimental models of head and neck squamous cell carcinoma","volume":"8","author":"Ekshyyan","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ijrobp.2013.06.2043_bib13","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1158\/1535-7163.MCT-05-0400","article-title":"Targeting the Akt\/mammalian target of rapamycin pathway for radiosensitization in breast cancer","volume":"5","author":"Albert","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ijrobp.2013.06.2043_bib14","doi-asserted-by":"crossref","first-page":"10040","DOI":"10.1158\/0008-5472.CAN-06-0802","article-title":"Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells","volume":"66","author":"Cao","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.ijrobp.2013.06.2043_bib15","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1158\/1078-0432.CCR-07-0955","article-title":"Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (everolimus) increases radiosensitivity in solid cancer","volume":"14","author":"Manegold","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2013.06.2043_bib16","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00280-007-0609-2","article-title":"Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines","volume":"62","author":"Aissat","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ijrobp.2013.06.2043_bib17","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.cell.2004.12.040","article-title":"The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damage induced apoptosis though inhibition of p21 translation","volume":"120","author":"Beuvink","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.ijrobp.2013.06.2043_bib18","doi-asserted-by":"crossref","first-page":"7031","DOI":"10.1158\/1078-0432.CCR-04-0361","article-title":"Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells","volume":"10","author":"Mondesire","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2013.06.2043_bib19","first-page":"1982","article-title":"Rapamycin enhances apoptosis and increases sensitivity to cisplatin in\u00a0vitro","volume":"55","author":"Shi","year":"1995","journal-title":"Cancer Res"},{"key":"10.1016\/j.ijrobp.2013.06.2043_bib20","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in post-menopausal hormone-receptor-positive advanced breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2013.06.2043_bib21","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III study","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2013.06.2043_bib22","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2013.06.2043_bib23","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s00280-011-1734-5","article-title":"A phase I study of everolimus plus low-dose weekly cisplatin for patients with advanced solid tumors","volume":"69","author":"Fury","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ijrobp.2013.06.2043_bib24","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1001\/archotol.125.2.177","article-title":"Detection of the proto-oncogene eIF4E in larynx and hypopharynx cancers","volume":"125","author":"Franklin","year":"1999","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.ijrobp.2013.06.2043_bib25","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1089\/10507250152740939","article-title":"Expression of eukaryotic translation initiation factors 4E and 2alpha correlates with progression of thyroid carcinoma","volume":"11","author":"Wang","year":"2001","journal-title":"Thyroid"},{"key":"10.1016\/j.ijrobp.2013.06.2043_bib26","doi-asserted-by":"crossref","first-page":"5901","DOI":"10.1158\/0008-5472.CAN-10-0192","article-title":"Genomic and biologic characterization of exon 4 KRAS mutations in human cancer","volume":"70","author":"Janakiraman","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.ijrobp.2013.06.2043_bib27","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.1200\/JCO.2011.38.2994","article-title":"Comparative genomic analysis of primary versus metastatic colorectal carcinomas","volume":"30","author":"Vakiani","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2013.06.2043_bib28","doi-asserted-by":"crossref","first-page":"4240","DOI":"10.1200\/JCO.2010.30.4154","article-title":"Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer","volume":"28","author":"Reidy","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2013.06.2043_bib29","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1200\/JCO.2007.14.0988","article-title":"Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors","volume":"26","author":"O'Donnell","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2013.06.2043_bib30","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1056\/NEJMoa032641","article-title":"Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer","volume":"350","author":"Bernier","year":"2004","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ijrobp.2013.06.2043_bib31","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa032646","article-title":"Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck","volume":"350","author":"Cooper","year":"2004","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ijrobp.2013.06.2043_bib32","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/S0360-3016(96)00430-0","article-title":"Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced head and neck cancer: Final report of a randomized trial","volume":"36","author":"Bachaud","year":"1996","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2013.06.2043_bib33","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/jso.21438","article-title":"Induction chemotherapy in the management of head and neck cancer","volume":"101","author":"Fury","year":"2010","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.ijrobp.2013.06.2043_bib34","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/hed.21179","volume":"32","author":"Adelstein","year":"2010","journal-title":"Head Neck"},{"key":"10.1016\/j.ijrobp.2013.06.2043_bib35","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.oraloncology.2012.02.021","article-title":"The PI3K\/Akt\/mTOR signalling pathway is active in salivary gland cancer and implies different functions and prognoses depending on cell localisation","volume":"48","author":"Ettl","year":"2012","journal-title":"Oral Oncol"},{"key":"10.1016\/j.ijrobp.2013.06.2043_bib36","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s10637-009-9269-x","article-title":"The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines","volume":"28","author":"Ma","year":"2009","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.ijrobp.2013.06.2043_bib37","doi-asserted-by":"crossref","first-page":"e727","DOI":"10.1200\/JCO.2011.36.2095","article-title":"Salivary duct carcinoma: Targeting the phosphatidylinositol 3-kinase pathway by blocking mammalian target of rapamycin with temsirolimus","volume":"29","author":"Piha-Paul","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2013.06.2043_bib38","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1126\/science.1206923","article-title":"Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1","volume":"333","author":"Agrawal","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.ijrobp.2013.06.2043_bib39","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1002\/cncr.27986","article-title":"A phase I study of everolimus plus docetaxel + cisplatin as induction chemotherapy for patients with locally and\/or regionally advanced head and neck cancer","volume":"119","author":"Fury","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2013.06.2043_bib40","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1158\/1078-0432.CCR-05-2173","article-title":"PIK3CA mutations in head and neck squamous cell carcinoma","volume":"12","author":"Qiu","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2013.06.2043_bib41","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1002\/ijc.23217","article-title":"Novel mutant enriched sequencing identified high frequency of PIK3CA mutations in pharyngeal cancer","volume":"122","author":"Qiu","year":"2008","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ijrobp.2013.06.2043_bib42","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1126\/science.1208130","article-title":"The mutational landscape of head and neck squamous cell carcinoma","volume":"333","author":"Stransky","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.ijrobp.2013.06.2043_bib43","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1200\/JCO.2012.43.2716","article-title":"Biomarker-directed therapy of squamous carcinomas of the head and neck: Targeting PI3K\/PTEN\/mTOR pathway","volume":"31","author":"Holsinger","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2013.06.2043_bib44","doi-asserted-by":"crossref","first-page":"9398","DOI":"10.1128\/JVI.00974-10","article-title":"The human papillomavirus type 16 E6 oncoprotein activates mTORC1 signaling and increases protein synthesis","volume":"84","author":"Spangle","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.ijrobp.2013.06.2043_bib45","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1158\/2159-8290.CD-12-0537","article-title":"Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers","volume":"3","author":"Pickering","year":"2013","journal-title":"Cancer Discov"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301613027508?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301613027508?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T04:43:03Z","timestamp":1716007383000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301613027508"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S0360301613027508"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2013.06.2043","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]}}}